In people with obesity and type 2 diabetes, persistently high levels of myostatin and interleukin-6 are linked to muscle loss, worsening insulin resistance, and brain inflammation, which may accelerate both physical and cognitive decline.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether elevated myostatin and IL-6 levels are consistently associated with muscle wasting, insulin resistance, and neuroinflammation across diverse populations with obesity and type 2 diabetes.
A systematic review and meta-analysis of at least 20 studies measuring serum myostatin and IL-6 alongside muscle mass (DXA), HOMA-IR, and neuroinflammatory biomarkers (e.g., CSF IL-6, GFAP) in adults with obesity or type 2 diabetes, with pooled effect sizes and heterogeneity analysis.
Whether interventions that reduce myostatin or IL-6 levels improve muscle mass, insulin sensitivity, or neuroinflammation in metabolic disease.
A double-blind RCT of 100 adults with type 2 diabetes and sarcopenia randomized to 12 weeks of myostatin inhibitor (e.g., follistatin-based therapy) or placebo, measuring changes in lean mass (DXA), HOMA-IR, and serum neuroinflammatory markers (e.g., CSF IL-6, TNF-α) as primary endpoints.
Whether persistently high myostatin and IL-6 levels predict future muscle loss, insulin resistance, or cognitive decline in individuals with metabolic disease.
A prospective cohort study of 400 adults with prediabetes followed for 5 years, measuring annual serum myostatin and IL-6 alongside lean mass (DXA), HOMA-IR, and cognitive performance (MoCA), adjusting for age, sex, BMI, and physical activity.
The association between serum myostatin and IL-6 levels and concurrent measures of muscle mass, insulin resistance, and neuroinflammation in a population with metabolic disease.
A cross-sectional analysis of 300 adults with type 2 diabetes, measuring serum myostatin and IL-6 alongside grip strength, HOMA-IR, and plasma CRP, adjusting for age, sex, BMI, and medication use.
Whether extreme elevations in myostatin or IL-6 correlate with rapid muscle and cognitive decline in individuals with metabolic disease.
A case series of 5 individuals with type 2 diabetes and HbA1c >9% who exhibit both severe sarcopenia (SARC-F ≥11) and cognitive impairment (MoCA <18) alongside serum myostatin and IL-6 levels >2 SD above population mean.